Common use of Allegations Clause in Contracts

Allegations. 1. The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the ▇▇▇▇▇-▇▇▇▇▇▇ Act ("▇▇▇▇▇-▇▇▇▇▇▇"), created the regulatory mechanism under which the United States Food and Drug Administration can approve generic pharmaceuticals. In 2015, sales of generic pharmaceuticals in the United States were estimated at $74.5 billion dollars. Today, the generic pharmaceutical industry accounts for approximately 88% of all prescriptions written in the United States. 2. Heritage, a privately held company formed in 2006, markets a variety of products in a number of therapeutic categories, including but not limited to: cardiovascular, metabolic disease, anti-infective and pain management. 3. ▇▇▇▇▇▇ participated in a conspiracy to suppress and eliminate competition by allocating customers, rigging bids, and fixing and maintaining prices for doxycycline hyclate delayed release sold in the United States, from in or about April 2013 and continuing until at least December 2015, in violation of the ▇▇▇▇▇▇▇ Antitrust Act, 15 U.S.C. § 1. ▇▇▇▇▇▇ participated in a conspiracy to suppress and eliminate competition by allocating customers and fixing and maintaining prices for glyburide sold in the United States, from in or about April 2014 and continuing until at least December 2015, in violation of the ▇▇▇▇▇▇▇ Antitrust Act, 15 U.S.C. § 1. (“Relevant Conduct”).

Allegations. 1. The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the ▇▇▇▇▇-▇▇▇▇▇▇ Act ("▇▇▇▇▇-▇▇▇▇▇▇"), created the regulatory mechanism under which the United States Food and Drug Administration can approve generic pharmaceuticals. In 2015, sales of generic pharmaceuticals in the United States were estimated at $74.5 billion dollars. Today, the generic pharmaceutical industry accounts for approximately 88% of all prescriptions written in the United States. 2. Heritage, a privately held company formed in 2006, markets a variety of products in a number of therapeutic categories, including but not limited to: cardiovascular, metabolic disease, anti-infective and pain management. 3. ▇▇▇▇▇▇ participated in a conspiracy to suppress and eliminate competition by allocating customers, rigging bids, and fixing and maintaining prices for doxycycline hyclate delayed release sold in the United States, from in or about April 2013 and continuing until at least December 2015, in violation of the ▇▇▇▇▇▇▇ Antitrust Act, 15 U.S.C. § 1. ▇▇▇▇▇▇ participated in a conspiracy to suppress and eliminate competition by allocating customers and fixing and maintaining prices for glyburide sold in the United States, from in or about April 2014 and continuing until at least December 2015, in violation of the ▇▇▇▇▇▇▇ Antitrust Act, 15 U.S.C. § 1. (“Relevant Conduct”).